Yingli Green Energy Hold. Co. Ltd. (YGE), Yahoo! Inc. (YHOO), Dell Inc. (DELL), The Dow Chemical Company (DOW), Frontier Communications (FTR), Gilead Sciences, Inc. (GILD), LNG Partners (GMLP), Genuine Parts Company (GPC) and Human Genome Sciences (HGSI) had ratings and price targets on them adjusted by analysts.
Yingli Green Energy Hold. Co. Ltd. (YGE) was downgraded by Miller Tabak from a "Neutral" rating to a "Sell" rating.
Yahoo! Inc. (YHOO) was downgraded by Credit Agricole from a "Buy" rating to an "Underperform" rating.
Dell Inc. (DELL) was downgraded by Citigroup (C) from a "Buy" rating to a "Neutral" rating.
The Dow Chemical Company (DOW) was downgraded by Gilford Securities from a "Hold" rating to a "Sell" rating.
Frontier Communications (FTR) was downgraded by Hudson Securities from a "Buy" rating to a "Hold" rating.
Gilead Sciences, Inc. (GILD) was downgraded by Sanford C. Bernstein from an "Outperform" rating to a "Market Perform" rating.
Golar LNG Partners (GMLP) was downgraded by Citigroup from a "Buy" rating to a "Neutral" rating.
Genuine Parts Company (GPC) was downgraded by Gabelli from a "Buy" rating to a "Hold" rating.
Human Genome Sciences (HGSI) was downgraded by RBC Capital from an "Outperform" rating to a "Sector Perform" rating. They placed a price target of $10.00 on the company, down from $15.00.
Showing posts with label Human Genome Sciences. Show all posts
Showing posts with label Human Genome Sciences. Show all posts
Wednesday, February 22, 2012
Friday, December 30, 2011
Human Genome Sciences (HGSI) Ratings, Price Targets
Updates on Human Genome Sciences (NASDAQ: HGSI) ratings and price targets.
Human Genome Sciences (NASDAQ: HGSI) had its “Neutral” rating reiterated by Goldman Sachs (NYSE: GS).
Citigroup (NYSE: C) lowered their price target on Human Genome Sciences to $8.00.
Barclays Capital (NYSE: BCS) initiated coverage on Human Genome Sciences. They placed an “Equal Weight” rating and a price target of $8.00 on the company.
Stifel Nicolaus lowered their price target on Human Genome Sciences (NASDAQ: HGSI) from $17.00 to $15.00. They have a “Buy” rating on the company.
Summer Street has a price target of $23.00 on Human Genome Sciences.
Human Genome Sciences (NASDAQ: HGSI) had its “Neutral” rating reiterated by Goldman Sachs (NYSE: GS).
Citigroup (NYSE: C) lowered their price target on Human Genome Sciences to $8.00.
Barclays Capital (NYSE: BCS) initiated coverage on Human Genome Sciences. They placed an “Equal Weight” rating and a price target of $8.00 on the company.
Stifel Nicolaus lowered their price target on Human Genome Sciences (NASDAQ: HGSI) from $17.00 to $15.00. They have a “Buy” rating on the company.
Summer Street has a price target of $23.00 on Human Genome Sciences.
Chesapeake (CHK) (HGSI) (LPS) (RAVN) (SCHW) Ratings Reiterated
Chesapeake Energy (NYSE: CHK), Human Genome Sciences (NASDAQ: HGSI), Lender Processing Services Incorporated (NYSE: LPS), Raven Industries, Inc. (NASDAQ: RAVN) and Charles Schwab (NASDAQ: SCHW) had ratings on the reiterated by analysts.
Jefferies Group (NYSE:JEF) reiterated its "Buy" rating on Chesapeake Energy (CHK).
Goldman Sachs (NYSE:GS) reiterated its "Neutral" rating on Human Genome Sciences (HGSI).
Zacks Investment Research reiterated its "Neutral" rating on Lender Processing Services Incorporated (LPS). They have a price target of $16.00 on the company.
Zacks Investment Research reiterated its "Outperform" rating on Raven Industries, Inc. (RAVN). They have a price target of $73.00 on the company.
Zacks Investment Research reiterated its "Neutral" rating on Charles Schwab (SCHW). They have a price target of $12.00 on the company.
Jefferies Group (NYSE:JEF) reiterated its "Buy" rating on Chesapeake Energy (CHK).
Goldman Sachs (NYSE:GS) reiterated its "Neutral" rating on Human Genome Sciences (HGSI).
Zacks Investment Research reiterated its "Neutral" rating on Lender Processing Services Incorporated (LPS). They have a price target of $16.00 on the company.
Zacks Investment Research reiterated its "Outperform" rating on Raven Industries, Inc. (RAVN). They have a price target of $73.00 on the company.
Zacks Investment Research reiterated its "Neutral" rating on Charles Schwab (SCHW). They have a price target of $12.00 on the company.
News (NWSA) (HGSI) (SUSQ) (BELFB) (UACL) (BC) Ratings, Price Targets
News Corp. (NASDAQ: NWSA), Human Genome Sciences (NASDAQ: HGSI), Susquehanna Bank (NASDAQ: SUSQ), Bel Fuse, Inc. (NASDAQ: BELFB), Universal Truckload Services, Inc. (NASDAQ: UACL) and Brunswick Co. (NYSE: BC) ratings and price targets.
News Corp. (NWSA) was upgraded by RBC Capital to a “Top Pick” rating.
Human Genome Sciences (HGSI) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS).
Susquehanna Bank (SUSQ) had its price target raised by Susquehanna to $10.00. The y have a “Buy” rating on the company.
Bel Fuse, Inc. (BELFB) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
Universal Truckload Services, Inc. (UACL) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Brunswick Co. (BC) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
News Corp. (NWSA) was upgraded by RBC Capital to a “Top Pick” rating.
Human Genome Sciences (HGSI) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS).
Susquehanna Bank (SUSQ) had its price target raised by Susquehanna to $10.00. The y have a “Buy” rating on the company.
Bel Fuse, Inc. (BELFB) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
Universal Truckload Services, Inc. (UACL) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Brunswick Co. (BC) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Wednesday, December 21, 2011
Datalink (DTLK) (HGSI) (HWAY) (EXXI) (EZPW) (FIO) Ratings, Price Targets
Datalink Corporation (NASDAQ: DTLK), Human Genome Sciences (NASDAQ: HGSI), Healthways, Inc. (NASDAQ: HWAY), Energy XXI (NASDAQ: EXXI), EZCORP, Inc. (NASDAQ: EZPW) and Fusion-Io Inc. (NYSE: FIO) ratings and price targets.
Datalink Corporation (DTLK) is now covered by Dougherty & Co. They have a “Buy” rating on the firm.
Human Genome Sciences (HGSI) had its price target lowered by Citigroup (NYSE:C) to $8.00.
Healthways, Inc. (HWAY) had its price target lowered by Piper Jaffray (NYSE:PJC) to $7.00.
Energy XXI (EXXI) was upgraded by Zacks Investment Research from a “Neutral” rating to an “Outperform” rating.
EZCORP, Inc. (EZPW) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Fusion-Io Inc. (FIO) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Datalink Corporation (DTLK) is now covered by Dougherty & Co. They have a “Buy” rating on the firm.
Human Genome Sciences (HGSI) had its price target lowered by Citigroup (NYSE:C) to $8.00.
Healthways, Inc. (HWAY) had its price target lowered by Piper Jaffray (NYSE:PJC) to $7.00.
Energy XXI (EXXI) was upgraded by Zacks Investment Research from a “Neutral” rating to an “Outperform” rating.
EZCORP, Inc. (EZPW) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Fusion-Io Inc. (FIO) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Thursday, November 17, 2011
Amarin (AMRN) (HGSI) (IM) (BBBY) (CHE) Ratings Reiterated
Amarin Co. plc (NASDAQ: AMRN), Human Genome Sciences (NASDAQ: HGSI), Ingram Micro Inc. (NYSE: IM), Bed Bath & Beyond Inc. (NASDAQ: BBBY) and Chemed Corporation (NYSE: CHE) had ratings on them reiterated by analysts.
Canaccord Genuity reiterated its "Buy" rating on Amarin Co. plc (AMRN).
Brean Murray reiterated its "Hold" rating on Human Genome Sciences (HGSI).
Needham & Company reiterated its "Buy" rating on Ingram Micro Inc. (IM).
Nomura reiterated its "Neutral" rating on Bed Bath & Beyond Inc. (BBBY).
Oppenheimer reiterated its "Hold" rating on Chemed Corporation (CHE).
Canaccord Genuity reiterated its "Buy" rating on Amarin Co. plc (AMRN).
Brean Murray reiterated its "Hold" rating on Human Genome Sciences (HGSI).
Needham & Company reiterated its "Buy" rating on Ingram Micro Inc. (IM).
Nomura reiterated its "Neutral" rating on Bed Bath & Beyond Inc. (BBBY).
Oppenheimer reiterated its "Hold" rating on Chemed Corporation (CHE).
Thursday, September 1, 2011
Zumiez (ZUMZ) (ADBE) (XRTX) (CBG) (HGSI) (DKS) Price Targets Changed
Zumiez (NASDAQ: ZUMZ), Adobe Systems (NASDAQ: ADBE), Xyratex Ltd. (NASDAQ: XRTX), CB Richard Ellis (NYSE: CBG), Human Genome Sciences (NASDAQ: HGSI) and Dick’s Sporting Goods (NYSE: DKS) had their price targets adjusted by analysts.
Zumiez (ZUMZ) had its price target lowered by Jefferies (NYSE:JEF) to $21.00.
Adobe Systems (ADBE) had its price target lowered by Piper Jaffray (NYSE:PJC) to $30.00.
Xyratex Ltd. (XRTX) had its price target lowered by Needham & Company from $13.00 to $11.00. They have a “Buy” rating on the company.
CB Richard Ellis (CBG) had its price target lowered by JPMorgan Chase & Co. (NYSE:JPM) to $26.00.
Human Genome Sciences (HGSI) had its price target lowered by Citigroup (NYSE:C) to $15.00.
Dick’s Sporting Goods (DKS) had its price target raised by FBR Capital from $40.00 to $42.00. They have an “Outperform” rating on the company.
Zumiez (ZUMZ) had its price target lowered by Jefferies (NYSE:JEF) to $21.00.
Adobe Systems (ADBE) had its price target lowered by Piper Jaffray (NYSE:PJC) to $30.00.
Xyratex Ltd. (XRTX) had its price target lowered by Needham & Company from $13.00 to $11.00. They have a “Buy” rating on the company.
CB Richard Ellis (CBG) had its price target lowered by JPMorgan Chase & Co. (NYSE:JPM) to $26.00.
Human Genome Sciences (HGSI) had its price target lowered by Citigroup (NYSE:C) to $15.00.
Dick’s Sporting Goods (DKS) had its price target raised by FBR Capital from $40.00 to $42.00. They have an “Outperform” rating on the company.
Hewlett-Packard (HPQ) (HGSI) (TTWO) (RIMM) (IBM) (KR) EPS Estimates Changed
Hewlett-Packard (NYSE:HPQ), Human Genome Sciences (NASDAQ:HGSI), Take Two Interactive (NASDAQ:TTWO), Research In Motion (NASDAQ:RIMM), IBM (NYSE:IBM) and Kroger (NYSE:KR) had EPS estimates adjusted by analysts.
Human Genome Sciences (HGSI) had its EPS estimates cut by Citigroup (NYSE:C). They have a price target of $15 on the company.
Take Two Interactive (TTWO) had its EPS estimates raised by Sterne Agee through 2013. They reiterated a "Buy" rating and price target of $21 on the company.
Hewlett-Packard (HPQ) had its EPS estimated cut by Credit Suisse (NYSE:CS). They have a price target of $30 on the company.
Research In Motion (RIMM) had its EPS estimates cut by Credit Suisse through 2013. They have a "Neutral" rating and a price target of $30 on the company.
IBM (IBM) EPS estimates were cut by Credit Suisse. They have a "Neutral" rating and a price target of $175 on the company.
Kroger (KR) EPS estimates lowered by Jefferies (NYSE:JEF). They have a "Buy" rating and price target of $27 on the company.
Human Genome Sciences (HGSI) had its EPS estimates cut by Citigroup (NYSE:C). They have a price target of $15 on the company.
Take Two Interactive (TTWO) had its EPS estimates raised by Sterne Agee through 2013. They reiterated a "Buy" rating and price target of $21 on the company.
Hewlett-Packard (HPQ) had its EPS estimated cut by Credit Suisse (NYSE:CS). They have a price target of $30 on the company.
Research In Motion (RIMM) had its EPS estimates cut by Credit Suisse through 2013. They have a "Neutral" rating and a price target of $30 on the company.
IBM (IBM) EPS estimates were cut by Credit Suisse. They have a "Neutral" rating and a price target of $175 on the company.
Kroger (KR) EPS estimates lowered by Jefferies (NYSE:JEF). They have a "Buy" rating and price target of $27 on the company.
Wednesday, August 24, 2011
Onyx (ONXX) (MINI) (AVNR) (MGRC) (HGSI) (OILT) (MDGN) Get New Coverage
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Mobile Mini, Inc. (NASDAQ: MINI), Avanir Pharmaceuticals Inc (NASDAQ: AVNR), Mcgrath Rentcorp (NASDAQ: MGRC), Human Genome Sciences (NASDAQ: HGSI), Oiltanking Partners (NASDAQ: OILT) and Medgenics (NASDAQ: MDGN) getting new analyst coverage.
Keybanc initiated coverage on Mobile Mini, Inc. (MINI). They placed a “Hold” rating on the company.
Summer Street Research initiated coverage on Onyx Pharmaceuticals, Inc. (ONXX). They placed a “Buy” rating and a price target of $49.00 on the company.
JMP Securities initiated coverage on Avanir Pharmaceuticals Inc (AVNR). They placed an “outperform” rating and a price target of $7.00 on the company.
Keybanc initiated coverage on Mcgrath Rentcorp (MGRC). They placed a “Buy” rating and a price target of $28.00 on the company.
Brean Murray initiated coverage on Human Genome Sciences (HGSI). They placed a “Buy” rating and a price target of $22.00 on the company.
Raymond James (NYSE:RJF) initiated coverage on Oiltanking Partners (OILT). They placed an “Outperform” rating on the company.
Maxim Group initiated coverage on Medgenics (MDGN). They placed a “Buy” rating and a price target of $8.00 on the company.
Keybanc initiated coverage on Mobile Mini, Inc. (MINI). They placed a “Hold” rating on the company.
Summer Street Research initiated coverage on Onyx Pharmaceuticals, Inc. (ONXX). They placed a “Buy” rating and a price target of $49.00 on the company.
JMP Securities initiated coverage on Avanir Pharmaceuticals Inc (AVNR). They placed an “outperform” rating and a price target of $7.00 on the company.
Keybanc initiated coverage on Mcgrath Rentcorp (MGRC). They placed a “Buy” rating and a price target of $28.00 on the company.
Brean Murray initiated coverage on Human Genome Sciences (HGSI). They placed a “Buy” rating and a price target of $22.00 on the company.
Raymond James (NYSE:RJF) initiated coverage on Oiltanking Partners (OILT). They placed an “Outperform” rating on the company.
Maxim Group initiated coverage on Medgenics (MDGN). They placed a “Buy” rating and a price target of $8.00 on the company.
Thursday, August 11, 2011
SunPower (SPWRA) (DIS) (GM) (ACAS) (BWC) (CTL) (HUM) (MYGN) EPS Estimates Changed
SunPower Co. (NASDAQ: SPWRA), Walt Disney (NYSE: DIS), General Motors (NYSE: GM), American Capital (NASDAQ: ACAS), Babcock & Wilcox Co. (NYSE: BWC), CenturyLink, Inc. (NYSE: CTL), Humana (NYSE: HUM) and Myriad Genetics (NASDAQ: MYGN) EPS estimates adjusted.
Citigroup (NYSE:C) slashed it EPS estimates on SunPower Co. (SPWRA). They have a “Hold” rating and a price targe of $16.50 on the company.
UBS AG (NYSE:UBS) lowered its EPS estimates on Walt Disney (DIS). They have a “Neutral” rating and a price target of $42.00 on the company.
Citigroup boosted its EPS estimates on General Motors (GM). They have a “Buy” rating and a price target $48.00 on the company.
UBS AG cut its EPS estimates on American Capital (ACAS). They have a “Buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) lowered its EPS estimates on Babcock & Wilcox Co. (BWC). They have a “Neutral” rating and a price target of $28.00 on the company.
UBS AG lowered its EPS estimates on CenturyLink, Inc. (NYSE: CTL). They have a “Buy” rating and a price target of $47.00 on the company.
Morgan Stanley (NYSE:MS) raised its EPS estimates on Humana (HUM). They have an “Equal Weight” rating on the company.
Goldman Sachs (NYSE:GS) cut its EPS estimates on Myriad Genetics (MYGN). They have a “Sell” rating and a price target of $18.00 on the company.
Citigroup (NYSE:C) slashed it EPS estimates on SunPower Co. (SPWRA). They have a “Hold” rating and a price targe of $16.50 on the company.
UBS AG (NYSE:UBS) lowered its EPS estimates on Walt Disney (DIS). They have a “Neutral” rating and a price target of $42.00 on the company.
Citigroup boosted its EPS estimates on General Motors (GM). They have a “Buy” rating and a price target $48.00 on the company.
UBS AG cut its EPS estimates on American Capital (ACAS). They have a “Buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) lowered its EPS estimates on Babcock & Wilcox Co. (BWC). They have a “Neutral” rating and a price target of $28.00 on the company.
UBS AG lowered its EPS estimates on CenturyLink, Inc. (NYSE: CTL). They have a “Buy” rating and a price target of $47.00 on the company.
Morgan Stanley (NYSE:MS) raised its EPS estimates on Humana (HUM). They have an “Equal Weight” rating on the company.
Goldman Sachs (NYSE:GS) cut its EPS estimates on Myriad Genetics (MYGN). They have a “Sell” rating and a price target of $18.00 on the company.
Monday, July 25, 2011
PepsiCo (PEP) (PM) (NYB) (NCR) (HGSI) (IR) Price Targets Changed
PepsiCo, Inc. (NYSE: PEP), Philip Morris (NYSE: PM), New York Community Bancorp, Inc. (NYSE: NYB), NCR Corp. (NYSE: NCR), Human Genome Sciences (NASDAQ: HGSI) and Ingersoll-Rand (NYSE: IR) price targets adjusted by analysts.
Morgan Stanley (NYSE: MS) lowered its price target on PepsiCo, Inc. (PEP) to $75.00. They have an “Overweight” rating on the company.
Stifel Nicolaus raised its price target on Philip Morris (PM) from $74.00 to $78.00. They have a “Buy” rating on the company.
FBR Capital cut its price target on New York Community Bancorp, Inc. (NYB) $19.00 to $17.00. They have an “Outperform” rating on the company.
Goldman Sachs (NYSE: GS) raised its price target on NCR Corp. (NCR) to $25.00. They have a “Buy” rating on the company.
RBC Capital lowered its price target on Human Genome Sciences (HGSI) from $38.00 to $32.00. They have an “Outperform” rating on the company.
UBS AG (NYSE: UBS) slashed its price target on Ingersoll-Rand (IR) from $50.00 to $45.00. They have a “Neutral” rating on the company.
Morgan Stanley (NYSE: MS) lowered its price target on PepsiCo, Inc. (PEP) to $75.00. They have an “Overweight” rating on the company.
Stifel Nicolaus raised its price target on Philip Morris (PM) from $74.00 to $78.00. They have a “Buy” rating on the company.
FBR Capital cut its price target on New York Community Bancorp, Inc. (NYB) $19.00 to $17.00. They have an “Outperform” rating on the company.
Goldman Sachs (NYSE: GS) raised its price target on NCR Corp. (NCR) to $25.00. They have a “Buy” rating on the company.
RBC Capital lowered its price target on Human Genome Sciences (HGSI) from $38.00 to $32.00. They have an “Outperform” rating on the company.
UBS AG (NYSE: UBS) slashed its price target on Ingersoll-Rand (IR) from $50.00 to $45.00. They have a “Neutral” rating on the company.
Friday, March 11, 2011
Glaxo (GSK) Hoping for More Gene-Research Loot
Now that GlaxoSmithKline (NYSE:GSK) has had its first success with Human Genome Sciences (NASDAQ:HGSI), they are hoping they'll be able to expand their offerings beyond the lupus drug, Benlysta, which was approved for use by the U.S. Food and Drug Administration.
Other drug studies being carried out by the partnership are in relationship to heart disease and diabetes.
In those categories they're still several years away from being marketed, and still must navigate successfully through the testing process before being considered for approval or not.
What's important for Glaxo and Human Genome is the understanding that there is an important part the mapping of the human genome can have on successful treatments.
Human Genome closed Thursday at $29.03, gaining $3.35, or 13.05 percent. Glaxo closed at $38.40, dropping $0.18, or 0.47 percent.
Other drug studies being carried out by the partnership are in relationship to heart disease and diabetes.
In those categories they're still several years away from being marketed, and still must navigate successfully through the testing process before being considered for approval or not.
What's important for Glaxo and Human Genome is the understanding that there is an important part the mapping of the human genome can have on successful treatments.
Human Genome closed Thursday at $29.03, gaining $3.35, or 13.05 percent. Glaxo closed at $38.40, dropping $0.18, or 0.47 percent.
Thursday, March 10, 2011
Biotech Doesn't Get Human Genome (HGSI) Bump
Negative economic news is weighing on the markets today, and even with the nice performance of Human Genome Sciences (NASDAQ:HGSI), it wasn't enough to push the sector up with them.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Human Genome Sciences' (HGSI) Lupus Drug Approved
Human Genome Sciences (NASDAQ:HGSI) had its lupus drug named Benlysta approved by the U.S. Food and Drug Administration; the first lupus drug approval in over 50 years.
Dr. Gary Gilkeson, chairman of the Lupus Foundation of America's medical scientific advisory council, said, "Getting this approval will lead to pharmaceutical companies wanting to continue to push and get other drugs approved."
There are approximatley 5 million people around the globe diagnosed with lupus, which can lead to chest pain, fatigue, skin rash and kidney damage, among other issues.
Side effects from the trials of Benlysta include diarrhea, fever, and nausea.
It is thought the drug should generate billions in sales around the world for Human Genome Sciences.
Now that Benlysta has been approved, hopes are companies like Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY) will go forward with some of their development programs for the disease.
GlaxoSmithKline (NYSE:GSK)shares moved up on the news after hours, as they'll distribute it in America, along with Human Genome Sciences.
Human Genome closed Wednesday at $25.68, up $0.01, or 0.04 percent. After hours trading was halted on the company. GlaxoSmithKline traded after hours at $39.50, up $0.92, or 2.38 percent.
Dr. Gary Gilkeson, chairman of the Lupus Foundation of America's medical scientific advisory council, said, "Getting this approval will lead to pharmaceutical companies wanting to continue to push and get other drugs approved."
There are approximatley 5 million people around the globe diagnosed with lupus, which can lead to chest pain, fatigue, skin rash and kidney damage, among other issues.
Side effects from the trials of Benlysta include diarrhea, fever, and nausea.
It is thought the drug should generate billions in sales around the world for Human Genome Sciences.
Now that Benlysta has been approved, hopes are companies like Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY) will go forward with some of their development programs for the disease.
GlaxoSmithKline (NYSE:GSK)shares moved up on the news after hours, as they'll distribute it in America, along with Human Genome Sciences.
Human Genome closed Wednesday at $25.68, up $0.01, or 0.04 percent. After hours trading was halted on the company. GlaxoSmithKline traded after hours at $39.50, up $0.92, or 2.38 percent.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Thursday, December 23, 2010
Human Genome Sciences' (Nasdaq:HGSI) Benlysta to Peak at $3.6 Billion
Human Genome Sciences (Nasdaq:HGSI) has started to receive coverage from Gleacher & Company, and they're definitely bullish on HGSI based on the potential of Benlysta sales, which they see ultimately peaking at $3.6 billion annually.
Gleacher said, "In our view, the FDA will likely request HGSI to conduct post-marketing studies in these patients. With regard to African American patients, we think the sample size in Phase III trials was too small to draw a reliable conclusion and the FDA should defer that decision to physicians until Benlysta is studied in a prospectively designed trial in this specific population."
Approval for the drug is expected to come in March 2011, and should be a strong performer based on physician feedback and unmet demand.
One factor weighing on Benlysta is if there are restrictions for those with severe active lupus nephritis and CNS lupus. Gleacher believes there wont' be total restrictions and the concerns the stock will suffer from it are not justified at the levels being proffered.
Gleacher projects Benlysta global sales of over $1 billion by 2014, and should peak in about 2023 at $3.6 billion. The numbers are modeled on a price of $30,000 for Benlysta in the U.S. and $24,000 outside the U.S.
Considering them conservative numbers, Gleacher estimates for every price increase of $5,000 the price target of the company should increase by about $4.
Gleacher started Human Genome Sciences off with a "Buy" rating. They closed Wednesday at $24.63, up $0.36, or 1.48 percent. Gleacher has a price target of $30 on them.
Gleacher said, "In our view, the FDA will likely request HGSI to conduct post-marketing studies in these patients. With regard to African American patients, we think the sample size in Phase III trials was too small to draw a reliable conclusion and the FDA should defer that decision to physicians until Benlysta is studied in a prospectively designed trial in this specific population."
Approval for the drug is expected to come in March 2011, and should be a strong performer based on physician feedback and unmet demand.
One factor weighing on Benlysta is if there are restrictions for those with severe active lupus nephritis and CNS lupus. Gleacher believes there wont' be total restrictions and the concerns the stock will suffer from it are not justified at the levels being proffered.
Gleacher projects Benlysta global sales of over $1 billion by 2014, and should peak in about 2023 at $3.6 billion. The numbers are modeled on a price of $30,000 for Benlysta in the U.S. and $24,000 outside the U.S.
Considering them conservative numbers, Gleacher estimates for every price increase of $5,000 the price target of the company should increase by about $4.
Gleacher started Human Genome Sciences off with a "Buy" rating. They closed Wednesday at $24.63, up $0.36, or 1.48 percent. Gleacher has a price target of $30 on them.
Tuesday, November 30, 2010
Human Genome Sciences (Nasdaq:HGSI) High on Baird's List
Baird analysts remain extremely bullish on Human Genome Sciences, Inc. (Nasdaq:HGSI), saying they would be "aggressive buyers" of the company.
They maintain their "Outperform" rating and price target on the company.
Baird analyst Christopher Raymond said, "While a three-month administrative delay beyond Benlysta's December 9 PDUFA is expected, the positive FDA AdCom vote did significantly de-risk the drug, in our view. Given this, and given the market misperceptions addressed herein, we would be aggressive buyers."
Citing a short window to PDUFA, their EPS estimates for the first quarter of 2011, full year 2011, and full year 2012 were lowered to $1.6 million, $161.4 million, and $793.8 million.
Human Genome Sciences closed Monday at $24.79, losing $0.11, or 0.44 percent. Baird has a price target of $32 on the company.
They maintain their "Outperform" rating and price target on the company.
Baird analyst Christopher Raymond said, "While a three-month administrative delay beyond Benlysta's December 9 PDUFA is expected, the positive FDA AdCom vote did significantly de-risk the drug, in our view. Given this, and given the market misperceptions addressed herein, we would be aggressive buyers."
Citing a short window to PDUFA, their EPS estimates for the first quarter of 2011, full year 2011, and full year 2012 were lowered to $1.6 million, $161.4 million, and $793.8 million.
Human Genome Sciences closed Monday at $24.79, losing $0.11, or 0.44 percent. Baird has a price target of $32 on the company.
Subscribe to:
Posts (Atom)